Akebia Therapeutics Inc (AKBA)
1.845
+0.16
(+9.17%)
USD |
NASDAQ |
Nov 04, 16:00
1.85
0.00 (0.00%)
After-Hours: 20:00
Akebia Therapeutics Enterprise Value: 386.51M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 386.51M |
| November 01, 2024 | 353.92M |
| October 31, 2024 | 347.61M |
| October 30, 2024 | 356.02M |
| October 29, 2024 | 358.12M |
| October 28, 2024 | 341.30M |
| October 25, 2024 | 332.89M |
| October 24, 2024 | 330.79M |
| October 23, 2024 | 332.89M |
| October 22, 2024 | 343.40M |
| October 21, 2024 | 286.63M |
| October 18, 2024 | 280.32M |
| October 17, 2024 | 278.22M |
| October 16, 2024 | 278.22M |
| October 15, 2024 | 274.01M |
| October 14, 2024 | 276.11M |
| October 11, 2024 | 276.11M |
| October 10, 2024 | 267.70M |
| October 09, 2024 | 267.70M |
| October 08, 2024 | 276.11M |
| October 07, 2024 | 276.11M |
| October 04, 2024 | 278.22M |
| October 03, 2024 | 276.11M |
| October 02, 2024 | 280.32M |
| October 01, 2024 | 267.70M |
| Date | Value |
|---|---|
| September 30, 2024 | 276.11M |
| September 27, 2024 | 278.22M |
| September 26, 2024 | 278.22M |
| September 25, 2024 | 276.11M |
| September 24, 2024 | 282.42M |
| September 23, 2024 | 274.01M |
| September 20, 2024 | 286.63M |
| September 19, 2024 | 286.63M |
| September 18, 2024 | 282.42M |
| September 17, 2024 | 286.63M |
| September 16, 2024 | 292.94M |
| September 13, 2024 | 305.55M |
| September 12, 2024 | 301.35M |
| September 11, 2024 | 301.35M |
| September 10, 2024 | 309.76M |
| September 09, 2024 | 297.14M |
| September 06, 2024 | 282.42M |
| September 05, 2024 | 288.73M |
| September 04, 2024 | 291.88M |
| September 03, 2024 | 295.04M |
| August 30, 2024 | 324.48M |
| August 29, 2024 | 318.17M |
| August 28, 2024 | 320.27M |
| August 27, 2024 | 318.17M |
| August 26, 2024 | 324.48M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-32.82M
Minimum
Nov 29 2022
1.776B
Maximum
Jun 29 2020
363.96M
Average
277.79M
Median
Jan 24 2024
Enterprise Value Benchmarks
| Corcept Therapeutics Inc | 4.866B |
| Bioventus Inc | 1.282B |
| Eli Lilly and Co | 792.96B |
| NovaBay Pharmaceuticals Inc | 3.645M |
| Palatin Technologies Inc | 13.74M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.582M |
| Revenue (Quarterly) | 43.65M |
| Total Expenses (Quarterly) | 52.37M |
| EPS Diluted (Quarterly) | -0.04 |
| Gross Profit Margin (Quarterly) | 60.94% |
| Profit Margin (Quarterly) | -19.66% |
| Earnings Yield | -11.21% |
| Normalized Earnings Yield | -11.58 |